SAROGLITAZAR

SAROGLITAZAR is an insulin sensitiser used to treat diabetic dyslipidaemia/hypertriglyceridemia in type-2 diabetic patients, which is not controlled by statins (lipid-lowering agents) alone. SAROGLITAZAR has both lipid and glucose-lowering effects in a single molecule, thereby helping lower blood triglycerides and blood glucose levels. Diabetic dyslipidaemia is characterised by increased triglyceride levels, low-density lipoproteins (LDL) and decreased high-density lipoprotein (HDL) levels. This condition is common in people with type-2 diabetes mellitus.
 
SAROGLITAZAR contains ‘Saroglitazar’, which has dual Peroxisome Proliferator-Activated Receptor (PPAR)-α/γ agonist having a strong PPAR-alpha effect and moderate PPAR-gamma effect. PPAR-alpha reduces the synthesis and secretion of triglycerides and increases lipolysis and hepatic oxidation of fatty acids. It also induces an increase in the synthesis of HDL cholesterol. PPAR-gamma reduces the metabolic burden on the liver and muscle and promotes glucose utilisation. It improves post-absorptive insulin-mediated suppression of hepatic glucose output. Thereby, SAROGLITAZAR helps in lowering blood triglycerides and blood glucose levels.
 
You are advised to take SAROGLITAZAR for as long as your doctor has prescribed it, depending on your medical condition. In some cases, you may experience certain common side effects, such as stomach inflammation, nausea, vomiting, weakness, chest discomfort, dizziness, and fever. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are recommended to consult your doctor if you experience these side effects persistently.
 
Consult your doctor if you are pregnant. It is not known if SAROGLITAZAR is excreted into breastmilk; therefore, nursing mothers should avoid taking SAROGLITAZAR. SAROGLITAZAR should not be given to children as safety and effectiveness have not been established. SAROGLITAZAR should be used with caution in patients with kidney or liver impairment and in elderly patients. Avoid alcohol consumption while taking SAROGLITAZAR as it might cause unpleasant side effects. SAROGLITAZAR might cause dizziness, so drive with caution. Inform your doctor about all the medications you are taking and your health condition to rule out any unpleasant side effects.

SAROGLITAZAR is an insulin sensitiser used to treat diabetic dyslipidaemia/hypertriglyceridemia in type-2 diabetes, which is not controlled by statins alone. SAROGLITAZAR has demonstrated a reduction of triglycerides (TG), Low-Density Lipoprotein (LDL) cholesterol, non-high-density Lipoprotein (non-HDL) cholesterol, Very Low-Density Lipoprotein (VLDL) cholesterol, and an increase in HDL cholesterol. It has also shown glycemic indices by lowering the fasting plasma glucose and glycosylated haemoglobin in diabetic patients. SAROGLITAZAR has dual Peroxisome Proliferator-Activated Receptor (PPAR)-α/γ agonist having strong PPAR-alpha effect and moderate PPAR-gamma effect. PPAR-alpha reduces the synthesis and secretion of triglycerides and increases lipolysis and hepatic oxidation of fatty acids. It also induces an increase in the synthesis of HDL cholesterol. PPAR-gamma reduces the metabolic burden on the liver and muscle, promotes glucose utilisation, and improves post-absorptive insulin-mediated suppression of hepatic glucose output. SAROGLITAZAR has both lipid and glucose-lowering effects in a single molecule; this helps in lowering blood triglycerides and blood glucose levels as well. It also helps in improving insulin resistance. SAROGLITAZAR offers a superior safety profile, greater efficacy on lipid regulation, and excellent glycaemic control.

• Gastritis (stomach inflammation)
• Nausea
• Vomiting
• Asthenia (weakness)
• Chest discomfort
• Dizziness
• Pyrexia (fever)